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Coronary artery diseaseBackground: Data on procedural and clinical outcomes of the everolimus-eluting bioresorbable vascular scaffold
(BVS, Abbott) in percutaneous coronary intervention in a real-world setting is limited. Early and mid-term clin-
ical outcomes of the BVS in a real-world population were investigated in this single centre study.
Methods: Patients treated with the BVS in the St. Antonius Hospital from April 2012 to February 2015 were in-
cluded in a prospective single centre registry. Procedural success deﬁned as b20% residual restenosis and 30-
day and 6-month clinical outcome were investigated. Cumulative event rates were expressed using Kaplan−-
Meier method.
Results: A total of 108 patientswere included in the study, including patients with ST-segment elevationmyocar-
dial infarction (STEMI) 18.5%, non-STEMI 22.2% and unstable angina 9.3%. In total 125 lesions were treated with
the BVS, of which 48.8% B2/C type lesions including 19.2% bare metal or drugs-eluting in-stent restenosis. Proce-
dural angiographic success was achieved in 99.2% of all patients. Clinical follow-up rate was 100% at 30-day and
87% at 6-month. The rate of cardiac death, target vessel revascularization and deﬁnite stent thrombosis was 0%,
0.9% and 0.9% at 30-day and 0.9%, 5.6% and 1.9% at 6-month. The composite end point of target lesion failure (Car-
diac death, target lesion myocardial infarction MI and target lesion revascularization) was 1.9% at 30-day and
5.6% at 6-month, respectively.
Conclusions: The use of the BVS in a real-world setting demonstrated excellent procedural success and acceptable
mid-term clinical outcomes. The rate of deﬁnite scaffold thrombosis was not dissimilar to other BVS registries.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In the last decades innovations in metallic stent technology signiﬁ-
cantly improved the efﬁcacy and safety of percutaneous coronary inter-
ventions (PCIs). Drugs-elutingmetallic stents (DES) are the current gold
standard in this ﬁeld with enhanced radial strength, thin struts and
polymer-coated drugs-elution to prevent acute recoil, early restenosis
and stent thrombosis. Despite these improvements DES remain at risk
for the occurrence of very late restenosis or stent thrombosis andmetal-
lic stents impede surgical revascularization in long stented coronary
segments. The Absorb bioresorbable vascular scaffold (BVS; Abbott Vas-
cular, Santa Clara, USA) was designed to overcome drawbacks ofional Cardiology, St. Antonius
erlands.
Teeuwen).
eliability and freedom from bias
ts of interest regarding the con-
. This is an open access article undermetallic stents by full scaffold reabsorption within 2 to 4 years and po-
tential restoration of coronary vasomotion. [1] The BVS consists of bio-
resorbable poly L-lactate acid (PLLA) backbone that delivers
temporary support mounted with anti-proliferative everolimus to in-
hibit neointima formation. In the ABSORB B trial, the BVS showed stable
luminal dimensions and favourable clinical results at three years in sim-
ple de novo lesions. [2] Currently, the BVS is widely available and oper-
ators gaining experiences in all type of lesions. [3] Whether these
favourable results in de novo lesions can be extrapolated to a real-
world population with more moderate and high-risk lesions is yet to
be determined. In this single centre study we examined the procedural
and clinical outcome of the BVS in an unselected real-world population.
2. Methods and materials
The BVS was introduced in the St. Antonius Hospital in April 2012
and the use steadily increased over time after certiﬁed training of all in-
terventional cardiologists. All operators were trained according to opti-
mal BVS implantation rules, including predilatation to maximumthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline clinical characteristics
Number of patients 108
Age (years) mean ± SD 59.4 ± 12.0
Male, n (%) 75 (69.4)
Current smoker, n (%) 33 (30.6)
Diabetes mellitus, n (%) 21 (19.4)
Non-insulin dependent, n (%) 13 (12)
Insulin dependent, n (%) 8 (7.4)
Hypercholesterolaemia, n (%) 79 (73.1)
Hypertension, n (%) 61 (57.4)
Family history of cardiovascular disease, n (%) 57 (56.5)
History of PCI 27 (25)
History of CABG 5 (4.6)
Body mass index (kg/m2), mean ± SD 27 ± 3.6
Chronic kidney disease
eGFR N 60 ml/min 96 (88.9)
eGFR 60–30 ml/min 11 (10.2)
eGFR b 30 ml/min 1 (0.9)
Ejection fraction, mean ± SD 54.3 ± 8.0
Ejection fraction b30%, n (%) 2 (1.8)
Coronary artery disease, n (%)
One vessel 90 (83.3)
Two vessels 17 (15.7)
Three vessels 1 (0.9)
Indication PCI
Stable angina, n (%) 54 (50)
Unstable angina, n (%) 10 (9.3)
NSTEMI, n (%) 24 (22.2)
STEMI, n (%) 20 (18.5)
Anti-platelet therapy
P2Y12 inhibitor 108 (100)
Clopidogrel 58 (53.7)
Ticagrelor 39 (36.1)
Prasugrel 11 (10.2)
Preloaded N24 h prior to PCI 82 (75.9)
Preloaded periprocedural 26 (24.1)
Dual anti-platelet therapy (P2Y12 inhibitor + aspirin) 99 (91.7)
P2Y12 inhibitor + vitamin K antagonist 8 (7.4)
P2Y12 inhibitor + aspirin + vitamin K antagonist 1 (0.9)
Single lesion 88 (81)
Receiving both BVS and metallic stent 0 (0)
Multiple lesions 20 (19)
Receiving both BVS and metallic stent 8 (7.4)
Metallic stent in target vessel 2 (1.9)
Metallic stent in non-target vessel 6 (5.6)
Values are n (%) ormean± SD, standard deviation; PCI: percutaneous coronary interven-
tion; CABG: coronary artery bypass graft; eGFR: estimated glomerular ﬁltration rate; and
DAP: dual anti-platelet therapy.
Table 2
Lesion characteristics
Number of lesions 125
LM 0 (0)
LAD 58 (46.4)
RCA 37 (29.6)
LCX 29 (23.2)
Venous graft 1 (0.8)
Lesion type
Type A 17 (13.6)
Type B1 45 (36)
Type B2 44 (35.2)
Type C 17 (13.6)
Lesion length (mm) mean ± SD 15.8 ± 7.4
Lesion length N 20 mm 26 (20.8)
Lesion length N 30 mm 7 (5.6)
Ostial 4 (3.2)
Bifurcation 12 (9.6)
Thrombus present 15 (12)
In-stent restenosis 24 (19.2)
Chronic total occlusion 8 (6.4)
Values are n (%) ormean± SD; LM: leftmain; LAD: left anterior descending ar-
tery; RCA: right coronary artery; and LCX: left circumﬂex artery.
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crease of 2 Atmospheres every 5 s and post-dilatation at discretion of
the operator with non-compliant balloon to the maximum scaffold di-
ameter. All patients treated with the BVS were prospectively registered
in our single centre's database form April 2012 until February 2015.
Clinical follow-up was obtained at 1 March 2015 with a minimum of
30 days follow-up. The decision to implant a BVS was at the discretion
of the operator. The local medical ethical committee approved the
study. Informed written consent was obtained prior to the procedure.
The reference vessel diameter of the target lesion should be within the
range of available scaffold size (diameters b2.5 or N3.5 mm). There
were no other exclusion criteria for BVS implantation. The study device
(Absorb BVS, Abbott Vascular, Santa Clara, USA)was the same as the de-
vice used in the ABSORB B trial and has been described previously. [4].
All patients received dual anti-platelet therapy (DAPT) prior to treat-
ment with aspirin 100 mg and 75 mg clopidogrel daily in case of stable
angina and prasugrel 5/10 mg daily or 90 mg ticagrelor twice daily in
patients presenting with acute coronary syndrome. Patients already
on oral coagulation received only clopidogrel in stable coronary artery
disease or triple including aspirin and ticagrelor in case of acute coro-
nary syndromes. DAPT was advised for at least 12 months.
The study population consisted of real-world patients from stable
angina to acute coronary syndromes and patients with high-risk lesions
like ST-segment elevated myocardial infarction (STEMI) or bare metal
stent (BMS) and DES in-stent restenosis. Baseline clinical -and angio-
graphic characteristics were collected prospectively in an electronic da-
tabase. Experienced operators assessed all angiograms. The occurrence
of clinical end points was evaluated during clinical visit or by telephone
interview. If patients were lost to follow-up, there vital status was
checked in the national population registry (Dutch Central Bureau of
Statistics). All clinical events were veriﬁed with available medical re-
cords and adjudicated by two interventional cardiologists.
Angiographic success was deﬁned as b20% residual stenosis. Target
lesion revascularization (TLR) was deﬁned as any revascularization, ei-
ther percutaneous or surgical, within 5mmproximal or distal of the tar-
get lesion. Any revascularization in the target vessel or side-bracheswas
deﬁned as target vessel revascularization (TVR). The device-oriented
clinical end point target lesion failure (TLF) was a composite of cardiac
death, target lesion myocardial infarction and target lesion revasculari-
zation. Finally, the patient-oriented end point major adverse cardiac
events (MACE) is a composite of all cause mortality, any revasculariza-
tion and/or any myocardial infarction. The Third universal deﬁnition
of myocardial infarction guidelinewas followed to establish the diagno-
sis of myocardial infarction and the academic research consortium def-
inition was used to assess the occurrence of scaffold thrombosis. [5,6].
2.1. Statistical analysis
All dichotomous data are stated as frequencies and continuous data
are summarized asmeans± standard deviation (SD) or asmedianwith
interquartile ranges (IQ). Cumulative event rates are expressed using
the Kaplan–Meier method. Clinical events were censored at 30 days, 6
months, 1 and 2-year follow-up.
3. Results
3.1. Baseline clinical and lesion characteristics
A total of 108 patients received 144 scaffolds in 125 lesions. Baseline
clinical characteristics are described in Table 1. The study population
was predominantly male 69.4% with a mean age of 59.4 ± 12 years.
The incidence of kidney failure was low with 0.9% estimated glomeruli
ﬁltration rate (eGFR) b 30 ml/min and 88.9% eGFR N 60 ml/min. The
mean ejection fraction was 54.3 ± 8.0%. The indication for PCI was
50% stable angina, 9.3% unstable angina, 22.2% non ST-segment eleva-
tion myocardial infarction (NSTEMI) and 18.5% STEMI. Dual anti-
Table 3
Procedural characteristics
Number of scaffolds 144
Scaffolds per lesion
One scaffold, n % 111 (88.8)
Two scaffolds, n % 10 (8.0)
Three scaffolds, n % 3 (2.4)
Four scaffolds, n % 1 (0.8)
Predilatation 119 (95.2)
Mean balloon diameter (mm) 2.8 ± 0.4
Mean dilatation pressure (atm) ± SD 12.7 ± 2.4
Postdilatation 9 (7.2)
Non-compliant 9 (7.2)
Mean balloon diameter (mm) 3.7 ± 0.4
Mean dilatation pressure (atm) ± SD 17.1 ± 3.1
Cutting balloon 2 (1.6)
Scaffold length (mm) mean ± SD 20.9 ± 9.3
Scaffold diameter (mm) mean ± SD 3.1 ± 0.5
Maximum scaffold dilatation pressure mean ± SD 15.2 ± 2.6
Pre-procedural % of diameter stenosis mean ± SD 88 ± 11.4
Post-procedural % of diameter stenosis mean ± SD 1.6 ± 3.6
Use of OCT, n (%) 2 (1.6)
Use of IVUS, n (%) 1 (0.8)
TIMI ﬂow III post-procedural 125 (100)
Post-procedural success b20% residual diameter stenosis 124 (99.2)
Values are n (%) ormean± SD; SD: standard deviation; atm: atmosphere; OCT: optical co-
herence tomography; and IVUS: intra vascular ultrasound.
Fig. 1. Cumulative rate of target lesion failure. The black line represents the cumulative
rate of target lesion failure using the Kaplan–Meier method. The 95% conﬁdence interval
is expressed by the grey surface area.
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received P2Y12 inhibitor combined with oral anticoagulation and 0.9%
received triple therapy. Most patients 75.9% were preloaded with DAPT at
least 24 h prior to the procedure and 24.1% were preloaded immediately
prior to or during the procedure, of which 18.5% were STEMI patients.
Baseline lesion characteristics are shown in Table 2. The BVSwas im-
planted 46.4% in the left anterior descending artery (LAD), 29.6% in the
right coronary artery (RCA) and 23.2% in de left circumﬂex. One case of
DES in-stent restenosis in a venous bypass graft was treated with a BVS
and there were no cases with left main disease. The lesion classiﬁcation
according to the American College of Cardiology demonstrated 13.6%
type A lesions and 36%, 35.2% and 13.6% moderate to high complex
type B1, B2 and C lesions. The mean lesion length was 15.8 ± 7.4 mm
with 20.8% of the lesions N20 mm. The percentage of treated ostial -
and bifurcation lesions and chronic total occlusions was 3.2%, 9.6% and
6.4%. The indication for treatment of in-stent restenosis was 19.2% of
all cases.Table 4
Clinical follow-up.
Clinical follow-up, n (%) In-hospital⁎108 (100) 3
Non-cardiac death, n (%) 0 (0) 0
Cardiac death, n (%) 0 (0) 0
Myocardial infarction (MI), n (%) 1 (0.9) 2
Target vessel (TV-MI) 1 (0.9) 2
Non-target vessel 0 (0) 0
Target lesion revascularization (TLR), n (%) 0 (0) 1
Target vessel revascularization (TVR), n (%) 0 (0) 1
Non-target vessel revascularization, n (%) 0 (0) 0
Any revascularization, n (%) 0 (0) 1
PCI, n (%) 0 (0) 1
CABG, n (%) 0 (0) 0
Scaffold thrombosis (ST), n (%)
Deﬁnite 0 (0) 1
Probable 0 (0) 0
Possible 0 (0) 0
Composite end points
Target lesion failure (cardiac death, TV-MI, TLR, deﬁnite ST) 1 (0.9) 2
MACE (all cause death, any MI, any revascularization) 1 (0.9) 2
* Estimated Kaplan–Meier cumulative event rates, values are n (%); PCI: percutaneous corona
events.3.2. Procedural characteristics
A total of 144 scaffolds were implanted in 125 lesions. Procedural
characteristics are demonstrated in Table 3. One hundred eleven lesions
(88.8%) received one scaffold, 8%, 2.4% and 0.8% had two, three or four
scaffolds. Most lesions were predilatated (95.2%) and a few post-dilata-
tions (7.2%) with only non-compliant balloons were performed. Angio-
graphic post-procedural successwas 99.2%with TIMI IIIﬂow in all cases.
Two illustrative cases of BVS implantationwere imagedwith optical co-
herence tomography. The ﬁrst case demonstrated an in-stent restenosis
of overlapping drugs-eluting stents for an earlier treated chronic total
occlusion (Fig. 2) and the second case involved STEMI caused by stent
thrombosis of a ﬁrst generation sirolimus-eluting stent (Fig. 3).3.3. Clinical outcomes
In-hospital and clinical outcomes are summarized in Table 4. The
median follow-up was 319 days with 213–435 interquartile ranges.
Clinical follow-up was available in 99%, 85%, 37% and 13% of all patients
at 30 days, 6months, 1 and 2-years. Only three patients 2.7%were lost to
follow-up. Their vital status was checked in Dutch central bureau of sta-
tistics and they were all alive.0 days⁎ 108 (100) 6 months⁎ 94 (87) 12 months⁎41 (38) 24 months⁎ 14 (13)
(0) 1 (0.9) 1 (1.0) 1 (0.9)
(0) 1 (0.9) 2 (2.0) 2 (2.0)
(1.9) 4 (3.8) 5 (5.3) 5 (5.3)
(0.9) 3 (2.8) 4 (4.3) 4 (4.3)
(0) 1 (0.9) 1 (0.9) 1 (0.9)
(0.9) 4 (3.8) 4 (3.8) 4 (3.8)
(0.9) 6 (5.6) 7 (7.1) 7 (7.1)
(0) 1 (0.9) 1 (0.9) 1 (0.9)
(0.9) 7 (6.5) 8 (8.1) 8 (8.1)
(0.9) 6 (5.6) 7 (7.1) 7 (7.1)
(0) 2 (1.9) 2 (1.9) 2 (1.9)
(0.9) 2 (1.9) 2 (1.9) 2 (1.9)
(0) 0 (0) 0 (0) 0 (0)
(0) 1 (1.0) 2 (1.9) 2 (1.9)
(1.9) 6 (5.6) 8 (8.1) 8 (8.1)
(1.9) 9 (8.4) 11 (10.9) 11 (10.9)
ry intervention; CABG: coronary artery bypass grafting; andMACE: major adverse cardiac
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myocardial infarction in a NSTEMI case complicated by an occlusion of
a right ventricular side-branch in the right coronary artery. During fol-
low-up two patients experienced a deﬁnite scaffold thrombosis. One
case involved a subject diagnosedwith small cell long carcinoma several
months after scaffold implantation. During admission for pneumonia
and pericardial effusion a scaffold thrombosis occurred without inter-
ruption of dual anti-platelet therapy. Onemonth later she died after ad-
mission with diminished conscious state probably due to progressive
metastatic disease. The second scaffold thrombosis occurred in a subject
admitted with decompensated heart failure; atrial ﬁbrillation and non-
ST segment elevated myocardial infarction with a chronic total occlu-
sion of the midsegment of the LAD and thrombotic lesion in the
midsegment of the RCA. Oral anti-coagulation and clopidogrel was initi-
ated several days before scaffold implantation. Hewas readmitted three
days after BVS implantation in the RCA with a scaffold thrombosis
caused most presumably by cessation of clopidogrel.
Two cases were registered as cardiac deaths and possible scaffold
thrombosis. The ﬁrst subject was found dead in bed six months after
scaffold implantation no autopsy was performed. The second case in-
volved an unwitnessed cardiac arrest at 3 months with asystole as
ﬁrst rhythm documented. Resuscitation was stopped after pulseless
electric activity remained again no autopsy was performed.
Furthermore, the rate of target lesion revascularization (TLR) was
3.8%, of which only one TLR in the subgroup of in-stent restenosis treat-
ed with BVS. This case involved a DES in-stent restenosis of an earlier
stented venous graft connected to the RCA. Three months after scaffold
implantation an in-scaffold restenosis occurred and the native RCA was
recanalized percutaneously.Fig. 2. BVS for focal in-stent restenosis. The following case involved treatment with the biores
restenosis of an earlier recanalized chronic total occlusion in the RCA at the site of two ov
3.0 × 15 mm. The upper panels demonstrate the two and three dimensional optical coheren
ﬂow reserve was 0.72. The lower panels show the ﬁnal result after pre-dilatation with non-comAs a result, the patient oriented composite end point of target lesion
failure occurred in 1.9% and 5.6% at 30-day and 6-month and with a
MACE rate of 1.9% and 8.4%, respectively (Fig. 1).
4. Discussion
The results of this study demonstrated high rates of procedural suc-
cess (99.2%)with excellent short-term and acceptablemid-term clinical
outcomes for the BVS in a real-world population with 48.8% of complex
B2/C lesions including 18.5% STEMI's and a niche of 19.2% BMS or DES
in-stent restenosis.
The results observed in the study population are similar to the AB-
SORB EXTEND registry and the randomized ABSORB II study at 30-day.
On the contrary, the event rates in this study were increased at 6-
month and 1-year. [7,8] However, these earlier studies only included
simple de novo lesions with exclusion of complex lesions like ostial le-
sions, bifurcation lesions with side-branches N2 mm, saphenous vein
graft lesions, BMS or DES in-stent restenosis, totally occluded coronaries
(TIMI ﬂow 0) and STEMI (TIMI b1).
Our registry results are in line with earlier presented data of the
GHOST-EU registry and the AmsterdamMedical Center (AMC) registry.
[9,10] The GHOST-EU registry observed a target lesion failure rate of
2.2% and 4.4% at 30-day and 6-monthwith a rate of deﬁnite or probable
scaffold thrombosis of 1.5% and 2.1%, respectively. The AMC registry
demonstrated similar results concerning myocardial infarction, target
vessel and lesion revascularization, despite an increased rate of scaffold
thrombosis of 3.2% at 6-month.
This registry study observed a rate of deﬁnite or probable scaffold
thrombosis of 0.9% and 1.9% at 30-day and 6-month. Despite theorbable vascular scaffold (BVS; Abbott Vascular, Santa Clara, California) of a focal in-stent
erlapping Orsiro (Biotronik, Germany, Berlin) drug-eluting stents of 3.0 × 30 mm and
ce tomography of focal in-stent restenosis at 9 months follow-up. Additional fractional
pliant balloons at 18 Atmospheres and implantation of 3.0 × 18 mm BVS at 16 atm.
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registries from 0 to 3.2% at 6-month, the average scaffold thrombosis
rate is approximately 1% at 6-month in BVS registries and 0.9% in the
ABSORB II at 1-year. [8,11] Nevertheless, this rate is still doubled com-
pared to the observed rate of stent thrombosis in the Swedish SCAAR
registry with the use of new generation DES. They observed a rate of
probable and deﬁnite stent thrombosis of 0.2% at 30-day and 0.4% at 6
months with new generation DES (Endeavor Resolute, Medtronic;
Xience, Abbott Vascular; Promus, Boston Scientiﬁc). [12].
The properties of the BVS seem to mimic BMS and old generation
DES (Cypher, Johnson & Johnson; Taxus, Boston scientiﬁc) concerning
deliverability and implantation. The bulkier device is more difﬁcult to
implant, needs more adequate lesion preparation and provokes more
clinically important edge dissections. For example, one quarter of pa-
tients required further optimisation after demonstrating important
malapposition and scaffold undersizing with optical coherence tomog-
raphy guided BVS implantation [13]. More important, the relative
large strut size of 150 μm could cause microscopic intra-coronary ﬂow
disturbances, which enhances thrombus formation and potential early
scaffold thrombosis prior to neointimal coverage [14]. On the other
hand, the BVS could potentially prevent more very late adverse events
including restenosis and scaffold thrombosis compared to metallic
DES. Earlier data in theABSORBA and B trial's showed evidence of stable
luminal dimensions between one and three years, and potential late
lumen enlargement with restoration of vasomotion beyond three
years accompanied by full scaffold reabsorption. [2,15].
Whether, these observations can reduce the rate of adverse events at
long-term follow-up in de novo lesions and more complex all comer le-
sions is yet to be investigated in larger randomized trials like theFig. 3. BVS for stent thrombosis. A 47 year oldmale presentingwith an anterior ST-elevatedmyo
son & Johnson) implanted electively in 2010. The upper panels show the occluded stent and rec
revealed due to a large thrombus burden. In-stent neoatherosclerosis or plaque rupture seemsm
ﬁnal angiographic result after implantation of two connecting BVS of 3.5 × 28mmproximal and
optical coherence tomography pullback showed the result after the ﬁrst implanted in-stent BVABSORB III, ABSORB IV and the Amsterdam Investigator initiated absorb
all-comer strategy trial (AIDA), which are currently enrolling.
Of note, this study included a high number of cases treated for BMS
and DES in-stent restenosis with the BVS compared to other BVS regis-
tries. Although these lesions are generally prone for restenosis we ob-
served only one target vessel revascularization in lesions with in-stent
restenosis treatedwith the BVS. Ielasie et al., reported a similar small co-
hort of patients treated with the BVS for BMS and DES in-stent resteno-
sis with only one target vessel revascularization (4%) and no scaffold
thrombosis at 6-month [16]. The theoretical concept of temporary in-
stent scaffolding with maximum drug-elution, and thereby avoiding
multiple layer stent struts, seems an intuitive next step to reduce the
stimulus for repeated in-stent neointimal hyperplasia, and thereby po-
tentially improve the efﬁcacy of BMS –and DES in-stent restenosis
treatment.
5. Limitations
There are limitations to acknowledge. This study was limited by low
number of patients and therefore the clinical results remain explorato-
ry. Nevertheless, the results are in line with other BVS real-world regis-
tries [11]. Secondly, this studywas observational in nature. However, all
data were collected prospectively and the rate of lost to follow-up was
only 2.7% with full follow-up of their vital status. Finally, the decision
to implant the BVS was at discretion of the operator, this could lead to
treatment of a selected population. The average age of the study popu-
lation was slightly younger and more patients were treated for BMS or
DES in-stent restenosis. Nonetheless, all other baseline characteristics
were comparable to other all comer studies. [17].cardial infarction due to a very late stent thrombosis of a Cypher drugs-eluting stent (John-
analization after balloon inﬂations. The true aetiology of the stent thrombosis could not be
ost likely with little evidence of stent malapposition. The lower panels demonstrated the
3.5× 12mmdistally and high-pressure non-compliant post-dilation 4.0 × 12mm. The last
S of 3.5 × 28 mm with good strut apposition.
6 K. Teeuwen et al. / Clinical Trials and Regulatory Science in Cardiology 10 (2015) 1–66. Conclusion
This single centre study demonstrated excellent procedural success
and acceptable mid-term clinical outcome with the BVS in a real-
world population. The rate of scaffold thrombosis was not dissimilar
to other BVS registries. We eagerly await results of the AIDA trial to as-
sess the true potential of the BVS in all comer populations.
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